
    
      Participants who had completed all doses of study drug and the Week 24 visit of M16-002
      (NCT02719171; the lead-in study) were eligible to enroll in M16-244 (this study).
      Participants were allowed to either finish the Week 24 visit of the lead-in study and take
      the first dose of study drug for this study on the same day, or delay the start of this study
      up to 8 weeks if needed.
    
  